- Active not recruitingPHASE2
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).
This study looks at new drug combinations for advanced bowel cancer that has specific genetic markers (MSI-H or dMMR). It compares these combinations with existing treatments to see if they are more effective and safe for patients.
For: Colorectal CancerUnited States · Belgium · Canada - Active not recruitingPHASE1, PHASE2
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
This study looks at new drug combinations for advanced kidney cancer that has not responded to previous treatments. It aims to see how safe and effective these new combinations are.
For: Carcinoma, Renal CellUnited States · Australia · Canada